Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice
Dorottya Laczkó, Michael J. Hogan, Sushila A. Toulmin, et al.
Immunity (2020) Vol. 53, Iss. 4, pp. 724-732.e7
Open Access | Times Cited: 327

Showing 1-25 of 327 citing articles:

SARS-CoV-2 vaccines in development
Florian Krammer
Nature (2020) Vol. 586, Iss. 7830, pp. 516-527
Open Access | Times Cited: 2058
Immunological considerations for COVID-19 vaccine strategies
Mangalakumari Jeyanathan, Sam Afkhami, Fiona Smaill, et al.
Nature reviews. Immunology (2020) Vol. 20, Iss. 10, pp. 615-632
Open Access | Times Cited: 1022
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Namit Chaudhary, Drew Weissman, Kathryn A. Whitehead
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 11, pp. 817-838
Open Access | Times Cited: 939
Drug delivery systems for RNA therapeutics
Kalina Paunovska, David Loughrey, James E. Dahlman
Nature Reviews Genetics (2022) Vol. 23, Iss. 5, pp. 265-280
Open Access | Times Cited: 778
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
Annette B. Vogel, Isis Kanevsky, Ye Che, et al.
Nature (2021) Vol. 592, Iss. 7853, pp. 283-289
Open Access | Times Cited: 633
Nanomaterial Delivery Systems for mRNA Vaccines
Michael D. Buschmann, Manuel Carrasco, Suman Alishetty, et al.
Vaccines (2021) Vol. 9, Iss. 1, pp. 65-65
Open Access | Times Cited: 446
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
Mohamad‐Gabriel Alameh, István Tombácz, Emily Bettini, et al.
Immunity (2021) Vol. 54, Iss. 12, pp. 2877-2892.e7
Open Access | Times Cited: 428
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Shugang Qin, Xiaoshan Tang, Yu‐Ting Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 384
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
Naveenchandra Suryadevara, Swathi Shrihari, Pavlo Gilchuk, et al.
Cell (2021) Vol. 184, Iss. 9, pp. 2316-2331.e15
Open Access | Times Cited: 382
Lipids and Lipid Derivatives for RNA Delivery
Yuebao Zhang, Changzhen Sun, Chang Wang, et al.
Chemical Reviews (2021) Vol. 121, Iss. 20, pp. 12181-12277
Open Access | Times Cited: 381
The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
Sonia Ndeupen, Zhen Qin, Sonya Jacobsen, et al.
iScience (2021) Vol. 24, Iss. 12, pp. 103479-103479
Open Access | Times Cited: 379
Circular RNA vaccines against SARS-CoV-2 and emerging variants
Liang Qu, Zongyi Yi, Yong Shen, et al.
Cell (2022) Vol. 185, Iss. 10, pp. 1728-1744.e16
Open Access | Times Cited: 374
Self-assembled mRNA vaccines
Jeonghwan Kim, Yulia Eygeris, Mohit Gupta, et al.
Advanced Drug Delivery Reviews (2021) Vol. 170, pp. 83-112
Open Access | Times Cited: 366
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
Emma S. Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
Cell (2021) Vol. 184, Iss. 7, pp. 1804-1820.e16
Open Access | Times Cited: 349
SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation
Katlyn Lederer, Diana Castaño, Daniela Gómez, et al.
Immunity (2020) Vol. 53, Iss. 6, pp. 1281-1295.e5
Open Access | Times Cited: 342
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
Drew Weissman, Mohamad‐Gabriel Alameh, Thushan I. de Silva, et al.
Cell Host & Microbe (2020) Vol. 29, Iss. 1, pp. 23-31.e4
Open Access | Times Cited: 340
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
Alexandra Schäfer, Frauke Muecksch, Julio C. C. Lorenzi, et al.
The Journal of Experimental Medicine (2020) Vol. 218, Iss. 3
Open Access | Times Cited: 332
A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development
Yingzhu Li, Rumiana Tenchov, Jeffrey Smoot, et al.
ACS Central Science (2021) Vol. 7, Iss. 4, pp. 512-533
Open Access | Times Cited: 316
Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
Chunfeng Li, Audrey Lee, Lilit Grigoryan, et al.
Nature Immunology (2022) Vol. 23, Iss. 4, pp. 543-555
Open Access | Times Cited: 312
mRNA vaccine: a potential therapeutic strategy
Yang Wang, Ziqi Zhang, Jingwen Luo, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 302
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
Xiancai Ma, Fan Zou, Fei Yu, et al.
Immunity (2020) Vol. 53, Iss. 6, pp. 1315-1330.e9
Open Access | Times Cited: 279
Prospects for a safe COVID-19 vaccine
Barton F. Haynes, Lawrence Corey, Prabhavathi Fernandes, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 568
Closed Access | Times Cited: 267
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
Tianyang Mao, Benjamin Israelow, Mario A. Peña-Hernández, et al.
Science (2022) Vol. 378, Iss. 6622
Open Access | Times Cited: 238
SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond
Emily Bettini, Michela Locci
Vaccines (2021) Vol. 9, Iss. 2, pp. 147-147
Open Access | Times Cited: 236
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
Kevin O. Saunders, Esther Lee, Robert Parks, et al.
Nature (2021) Vol. 594, Iss. 7864, pp. 553-559
Open Access | Times Cited: 235
Page 1 - Next Page

Scroll to top